The nuclear receptor peroxisome proliferator-activated receptor ␥ (PPAR␥) is involved in glucose homeostasis and synthetic PPAR␥ ligands, the thiazolidinediones, a new class of antidiabetic agents that reduce insulin resistance and, as a secondary effect, reduce hepatic glucose output. PPAR␥ is highly expressed in normal human pancreatic islet ␣-cells that produce glucagon. This peptide hormone is a functional antagonist of insulin stimulating hepatic glucose output. Therefore, the effect of PPAR␥ and thiazolidinediones on glucagon gene transcription was investigated. After transient transfection of a glucagon-reporter fusion gene into a glucagon-producing pancreatic islet cell line, thiazolidinediones inhibited glucagon gene transcription when PPAR␥ was coexpressed. They also reduced glucagon secretion and glucagon tissue levels in primary pancreatic islets. A 5/3-deletion and internal mutation analysis indicated that a pancreatic islet cellspecific enhancer sequence (PISCES) motif within the proximal glucagon promoter element G1 was required for PPAR␥ responsiveness. This sequence motif binds the paired domain transcription factor Pax6. When the PISCES motif within G1 was mutated into a GAL4 binding site, the expression of GAL4-Pax6 restored glucagon promoter activity and PPAR␥ responsiveness. GAL4-Pax6 transcriptional activity was inhibited by PPAR␥ in response to thiazolidinedione treatment also at a minimal viral promoter. These results suggest that PPAR␥ in a ligand-dependent but DNA binding-independent manner inhibits Pax6 transcriptional activity, resulting in inhibition of glucagon gene transcription. These data thereby define Pax6 as a novel functional target of PPAR␥ and suggest that inhibition of glucagon gene expression may be among the multiple mechanisms through which thiazolidinediones improve glycemic control in diabetic subjects.
Peroxisome proliferator-activated receptor ␥ (PPAR␥)1 is a member of the ligand-regulated nuclear hormone receptor superfamily (1). Like other nuclear receptors, PPAR␥ comprises an amino-terminal ligand-independent transactivation domain (AF-1), a central DNA-binding domain, and a carboxyl-terminal ligand-binding domain that contains a second, ligand-dependent transactivation surface (AF-2) (1). PPAR␥ binds as a heterodimer with the 9-cis-retinoic acid receptor, RXR, to response elements in target genes to activate transcription. A typical PPRE consists of a direct repeat of hexamer half-sites, TGACCT, spaced by one nucleotide (DR-1) (1). PPAR and RXR occupy the 5Ј and 3Ј half-sites, respectively, and thus show a polarity in binding that is the opposite of that observed for other nuclear receptor-RXR heterodimers (1). Like other nuclear receptors, there is evidence that PPAR␥-RXR require the ligand-dependent recruitment of coactivator proteins like SRC-1, GRIP-1, pCIP, CBP, p300, DRIP205, and p120 (2-5) to effectively stimulate gene transcription. This recruitment is dependent on allosteric alterations in the AF-2 helical domain. A "mouse trap" model of receptor activa...